After demonstrating the ability to deliver L-siRNA to the lungs, we proceeded to test the potential of this respiratory administration for the delivery of L-WT1 siRNAs as an antitumoral therapy for melanoma metastases in vivo. This evidence concerns the gene WT1 and melanoma.